A share price of Quest Diagnostics, Inc. [DGX] is currently trading at $145.79, down -2.86%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The DGX shares have gain 2.57% over the last week, with a monthly amount glided 3.80%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Quest Diagnostics, Inc. [NYSE: DGX] stock has seen the most recent analyst activity on July 10, 2024, when Citigroup upgraded its rating to a Buy and also boosted its price target to $165 from $145. Previously, Leerink Partners started tracking the stock with Market Perform rating on February 26, 2024, and set its price target to $135. On February 07, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $155 on the stock. Barclays started tracking the stock assigning a Equal Weight rating and suggested a price target of $145 on January 03, 2024. BofA Securities upgraded its rating to a Buy and raised its price target to $160 on December 12, 2023. In a note dated May 02, 2023, BofA Securities downgraded an Neutral rating on this stock and revised its target price from $166 to $148.
Quest Diagnostics, Inc. experienced fluctuations in its stock price throughout the past year between $119.59 and $151.78. Currently, Wall Street analysts expect the stock to reach $154.91 within the next 12 months. Quest Diagnostics, Inc. [NYSE: DGX] shares were valued at $145.79 at the most recent close of the market. An investor can expect a potential return of 6.26% based on the average DGX price forecast.
Analyzing the DGX fundamentals
Trailing Twelve Months sales for Quest Diagnostics, Inc. [NYSE:DGX] were 9.35B which represents 2.52% growth. Gross Profit Margin for this corporation currently stands at 0.32% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.09%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.13 and Total Capital is 0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 143.59 points at the first support level, and at 141.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 149.27, and for the 2nd resistance point, it is at 152.75.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Quest Diagnostics, Inc. [NYSE:DGX] is 1.00. Further, the Quick Ratio stands at 0.91, while the Cash Ratio is 0.13. Considering the valuation of this stock, the price to sales ratio is 1.74, the price to book ratio is 2.45 and price to earnings (TTM) ratio is 19.66.
Transactions by insiders
Recent insider trading involved DELANEY MARK E, SVP & Chief Commercial Officer, that happened on Jul 24 ’24 when 420.0 shares were sold. SVP, Clinical Solutions, KUPPUSAMY KARTHIK completed a deal on Apr 29 ’24 to sell 1760.0 shares. Meanwhile, SVP & General Counsel PREVOZNIK MICHAEL E sold 5611.0 shares on Feb 29 ’24.
